Lim J, Malek R, Toh CC, et al. - A longitudinal Malaysia Prostate Cancer (M-CaP) Study investigating multi-ethnic Asian men with prostate cancer for describing the clinical and tumor characteristics, treatment patterns as well as disease outcomes.

• A total of 1,839 new patients with prostate cancer diagnosed between 2016 and 2018 from nine public urology referral centers across Malaysia were studied; the median age at diagnosis was 70 years.

• Patients were Chinese in majority (831, 45.2%), followed by Malays (704, 38.3%), Indians (124, 6.7%) and other races (181, 9.8%).

• In this multi-ethnic Asian population, the late stage at presentation remains a challenge.

• For stage III and stage IV diseases, curative radiotherapy and primary androgen deprivation therapy, respectively, were the most common treatments.

• The median overall survival and biochemical progression-free survival were 40.1 months and 19.2 months, respectively, for stage IV patients.

• It is imperative to early detect the disease to attain improvement in treatment outcome and survival of patients.